Jefferies initiated coverage of Damora Therapeutics (DMRA) on July 27, 2026. Analyst Akash Tewari issued a Buy rating for the stock. The firm set a price target of $50 per share. This objective represents a potential upside of over 73%. The company's shares previously closed at $28.82.
The positive outlook centers on DMR-001, a long-acting antibody for myeloproliferative neoplasms. Jefferies expects the drug to outperform competitors through superior efficacy and more convenient dosing. The firm also noted a strong strategy for front-line myelofibrosis treatment.
The market opportunity in essential thrombocythemia alone could justify most of the company's current valuation.